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Multi-valvular endocarditis
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Objective Seventy-seven cases of native valve infective endocarditis as determined by the Duke criteria, were
reviewed to determine the incidence and clinical features of multi-valvular endocarditis.
Methods Fourteen of 77 patients (18%) had multi-valvular endocarditis most commonly involving the mitral
and aortic valves. Staphylococcus aureus (43%) and viridans streptococci (36%) were the most common organisms
causing multi-valvular endocarditis.
Results Definite or probable vegetations were found in 50% of the patients by two-dimensional transthoracic
echocardiograph and/or transesophageal echocardiograph, and possible vegetations were detected in 21%. The
overall mortality in our series was 21%; 29% underwent valve replacement and 50% were treated medically.
The major complications of multi-valvular endocarditis were congestive heart failure (64%), acute renal failure
(50%), embolic events (21%), and splenic abscess/infarcts (21%).
Conclusions Our data suggests complications of multi-valvular endocarditis, compared with uni-valvular
endocarditis are similar except for heart failure. Heart failure is statistically more common in multi-valvular
endocarditis (P  0.002).
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INTRODUCTION
Infective endocarditis (IE) involving multiple cardiac valves is
uncommon. The majority of echocardiographically demon-
strated endocarditis occurs on a single valve; the involvement
of two valves occurs much less frequently, and triple- or quad-
ruple-valve involvement is extremely rare [1–6]. Demon-
stration of multi-valvular involvement in patients with
suspected IE is important. Mortality rate is more likely to be
higher in patients with infection of two or more valves than a
single valve and these patients might require early operation for
management of complications [7]. We reviewed the medical
records of 77 patients with documented IE to study the inci-
dence, presentation, outcome, and complications of multi-val-
vular endocarditis.
METHODS
The medical records of all adult patients with documented
native valve IE were reviewed. Endocarditis was defined using
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the Duke criteria [8]. The patients were admitted to Winthrop-
University Hospital, a 600-bed, tertiary care, teaching hospital
in Mineola, New York, between August 1990 and November
1994. Of 77 patients who met the Duke criteria for IE, 14
patients had multi-valvular endocarditis on the basis that sep-
ticemia was present in a febrile patient, with or without a new
or changing heart murmur, who had more than one cardiac
valve involvement demonstrated by two-dimensional (2-D)
transthoracic echocardiograph (TTE), or transesophageal echo-
cardiograph (TEE) images of vegetations, or by new regur-
gitation detected by Doppler echocardiography. Of 14 cases of
multi-valvular endocarditis reviewed, information pertaining
to demographic characteristics, predisposing factors, micro-
organisms involved, sites of infection, clinical and laboratory
features, outcome, and complications were analyzed. Twenty-
five patients with uni-valvular endocarditis were selected from
the remaining 63 patients as age-matched controls.
RESULTS
Results are summarized in Tables 1 and 2. Of 77 IE patients
reviewed, 14 patients (18%) had multiple-valve involvement.
These 14 patients were divided into two groups. Group I
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Figure 1 Transesophageal echocardiographic (TEE) images showing
large echodensities on the mitral valve and the aortic valve.
included seven patients with underlying heart disease (e.g.
mitral valve prolapse, rheumatic heart disease, con-
genital/acquired valvular diseases, a history of IE, etc.). Group
II included seven patients with or without other known pre-
disposing factors (e.g. alcohol abuse, steroid use, diabetes melli-
tus, etc.).
All 14 cases of multi-valvular endocarditis involved two
valves and there was no triple- or quadruple-valve endocarditis
in our series. The patients’ age range was 31–96 years (mean
65 years). The male : female ratio was 4.3, equally divided in
each group. In group I, the mean age was 62 years, whereas in
group II the mean age was 68 years. Predisposing factors, which
were found in various combinations in 11 of these 14 patients
(79%), were mitral valve prolapse (two patients; 14%), rheu-
matic heart disease (one patient; 7%), congenital valvular dis-
ease–mitral stenosis (one patient; 7%), acquired valvular disease–
aortic insufficiency (one patient; 7%), a history of IE (two
patients; 14%), recent permanent pacemaker placement (one
patient; 7%), recent dental procedure (two patients; 14%),
recent abdominal surgery (one patient; 7%), intravenous drug
abuse (one patient; 7%), alcohol abuse (one patient; 7%), steroid
use (one patient; 7%), and diabetes mellitus (two patients; 14%).
The etiologic micro-organisms found in these 14 patients were
Staphylococcus aureus in six patients (43%)—three patients in each
group; viridans streptococci (e.g. Streptococcus mutans, Strep-
tococcus sanguis, and Streptococcus mitis) in five patients (36%)—
three patients in group I and two patients in group II; and
enterococci in two patients (14%)—one patient in each group.
One patient in group II had two micro-organisms, Staphylococcus
aureus and Klebsiella pneumoniae. This patient was treated with
an anti-staphylococcal cephalosporin and an aminoglycoside,
but unfortunately died.
The valves most frequently involved were mitral and aortic
valves (12 of 14 patients; 86%)—six patients in each group.
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Mitral and tricuspid valves were involved in one patient in
group I, and the aortic and tricuspid valves were involved in
one patient in group II. We had no methicillin-resistant strains
among patients infected with S. aureus in our series.
All patients underwent 2-D TTE and Doppler echo-
cardiography and some patients underwent TEE when necess-
ary (Figure 1). We had no methicillin-resistant strains among
patients infected with S. aureus. Definite or probable vegetations
were found in seven of the patients (50%)—five patients in
group I and two patients in group II, and possible vegetations
were found in a further three of the 14 patients (21%)—one
patient in group I and two patients in group II. All patients
demonstrated on the Doppler echocardiogram mild to mod-
erate regurgitation of affected valves. Clinically, a new or chan-
ging murmur was detected in seven of the 14 patients (50%)—
two patients in group I and five patients in group II. Osler’s
nodes, Janeway lesions, splinter haemorrhages, or petechiae
were not, or rarely (in one to two patients), detected in the
majority of our patients. Thirteen of 14 patients (93%) presented
with fever (temperature 100.6 °F, 38 °C) and chills. Among
them, three patients (23%), all in group I, had temperatures
102 °F (38.8 °C). Microscopic haematuria was a common
finding (10 of 14 patients; 71%)—five patients in each group.
Erythrocyte sedimentation rate (ESR) was elevated in all
patients (100%) with a range of 26–108 mm/h. Two of 14
patients (14%), both in group II, had ESR  100 mm/h.
The overall mortality in our series was 21% (three of 14
patients)—one patient in group I and two patients in group
II. Four of 14 patients (29%) underwent surgical intervention
(multiple valve replacement or pacemaker replacement)—three
patients in group I and one patient in group II. Seven of
14 patients (50%) were discharged after prolonged antibiotic
therapy—three patients in group I and four patients in group
II. The major complications among these 14 patients, in various
combinations, were congestive heart failure (nine patients;
64%), acute renal failure (seven patients; 50%), embolic events
(i.e. pulmonary emboli (PE), cerebral vascular accidents, dis-
seminated intravascular coagulation, etc.) (three patients; 21%),
splenic abscess or infarct (three patients; 21%), persistent bac-
teremia (two patients; 14%), meningitis (one patient; 7%), and
liver necrosis (one patient; 7%). (Tables 1, 2) The characteristics
of the uni-valvular control group are shown in Table 3.
With the exception of congestive heart failure, the com-
plications of multi-valvular and uni-valvular endocarditis were
similar and not statistically different. Complications included
acute renal failure, cerebral vascular accident, and congestive
heart failure, and were not statistically different in patients with
multi- or uni-valvular endocarditis. Congestive heart failure
was a more frequent complication in the multi-valvular group,
which was statistically different (P  0.002). The valve replace-
ment surgery and mortality were not significantly different in
both groups. (Table 4).
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Table 3 Multi-valvular endocarditis in the Winthrop-
University Hospital case series: controls/complications
Number of patients = 14
Mean age (range) = 65 (31–96) years
Male : female ratio = 8 : 6
Predisposing factors = 11/14 patients (79%)
Mitral valve prolapse = 2/14 patients (14%)
Rheumatic heart disease = 1/14 patients (7%)
Congenital valvular disease (mitral stenosis) = 1/14 patients (7%)
Acquired valvular disease (aortic insufficiency) = 1/14 patients (7%)
History of infective endocarditis = 2/14 patients (14%)
Recent permanent pacemaker placement = 1/14 patients (7%)
Recent dental procedure = 2/14 patients (14%)
Recent abdominal surgery = 1/14 patients (7%)
Intravenous drug abuse = 1/14 patients (7%)
Etiologic micro-organisms
Staphylococcus aureus (MSSA) = 6/14 patients (43%)
Viridans streptococci (Streptococcus mutans, S. sanguis,
and S. mitis) = 5/14 patients (36%)
Enterococci = 2/14 patients (14%)
Staphylococcus aureus and Klebsiella pneumoniae (7%)
Sites of infection
Mitral valve and aortic valve = 12/14 patients (86%)
Mitral valve and tricuspid valve = 1/14 patients (7%)
Aortic valve and tricuspid valve = 1/14 patients (7%)
Echocardiogram
Definite/probable vegetation = 7/14 patients (50%)
Possible vegetation = 3/14 patients (21%)
No vegetation = 4/14 patients (29%)
Clinical and laboratory features
New or changing murmur = 7/14 patients (50%)
Osler’s nodes = 0/14 patients (0%)
Janeway lesions = 1/14 patients (7%)
Splinter hemorrhages = 0/14 patients (0%)
Petechiae = 2/14 patients (14%)
Fever (T  100.6 °F) = 13/14 patients (93%)
(T  102 °F) = 3/13 patients (23%)
Chills = 13/14 patients (93%)
Microscopic hematuria = 10/14 patients (71%)
Elevated ESR (20 mm/h) = 14/14 patients (100%)
ESR range = 26–108 mm/h (ESR  100 mm/h = 2/14 patients (14%))
Outcome and complications
Death = 3/14 patients (21%)
Surgical intervention (multi-valve replacement) = 4/14 patients
(29%)
Congestive heart failure = 9/14 patients (64%)
Acute renal failure = 7/14 patients (50%)
Embolic events = 3/14 patients (21%)
Splenic abscess/infarct = 3/14 patients (21%)
Persistent bacteremia = 2/14 patients (14%)
Meningitis = 1/14 patients (7%)
Liver necrosis = 1/14 patients (7%)
ESR, erythrocyte sedimentation rate.
© 2000 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 6, 207–212
Post-mortem results were not obtained on any patient. Path-
ology following valve replacement was available in three pat-
ients with multi-valvular endocarditis and four patients in the
uni-valvular group. Pathology reports were similar in both
groups and were reported as having acute organizing inflam-
mation, fibrin and calcium deposition associated with vascular
and fibroblastic proliferation on the removed valve leaflets. All
removed valve cells were negative for bacterial growth.
DISCUSSION
The occurrence of multi-valvular endocarditis is uncommon.
The majority of IE cases involves a single valve, and demon-
stration of two-, triple-, or even quadruple-valve involvement
by echocardiography is less frequent [1–6]. We reviewed the
medical records of patients who were admitted to our hospital
over a 4-year period with documented IE to determine the
incidence and presentation of multi-valvular endocarditis using
the Duke criteria [8]. We report here that among 77 patients
with documented IE reviewed, there were 14 patients (18%)
who had multi-valvular endocarditis, and 63 with uni-valvular
endocarditis. Twenty-five age matched patients with uni-val-
vular endocarditis were selected as age-matched controls. Four-
teen patients had two-valve involvement demonstrated by
echocardiography and there were no triple- or quadruple-valve
IE cases in our series.
The most common etiologic micro-organism in our series
was S. aureus (43%), which was responsible for multi-valvular
endocarditis in three patients in each group. Staphylococci,
which account for at least 30% of episodes of native valve IE,
are reported to be the most important cause in IE associated
with intravenous drug use (one case in our series) and in noso-
comial IE [9]. Staphyloccocus aureus is able to infect previously
normal heart valves (four patients in our series) and usually
causes an acute illness [9]. All of our strains of S. aureus were
methicillin sensitive. The second most common micro-organ-
isms in our patients with multi-valvular endocarditis were vir-
idans streptococci (36%), which included S. mitis, S. sanguis,
and S. mutans. Since the 1960s, the percentage of cases caused
by viridans streptococci has decreased to about 35% [10]. Two
patients (14%) in our series had enterococci as the etiologic
agent. Enterococci normally inhabit the gastrointestinal and
genitourinary tracts and are the cause in 5–10% of patients with
IE [11]. One patient (7%) in our series had polymicrobial IE.
This patient had no known predisposing factors, but presented
with aortic- and tricuspid-valve infection by S. aureus and K.
pneumoniae. Antibiotic therapy consisted of an anti-sta-
phylococcal cephalosporin plus an aminoglycoside until the
patient expired from internal haemorrhage from disseminated
intravascular coagulation.
Although there are reports that suggest that patients with
either infection of the aortic valve or infection of two or more
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Table 4 Complications of uni-valvular and multi-valvular endocarditis
Uni-valvular endocarditis Multi-valvular endocarditis Statistical
Complications (n = 25) (n = 14) significance
Congestive heart failure 4 (16%) 9 (64%) statistically significant (P  0.002)a
Acute renal failure 4 (16%) 6 (43%) not significant
Cerebrovascular accident 2 (8%) 1 (7%) not significant
Valve replacement surgery 4 (16%) 3 (21%) not significant
Death 2 (18%) 3 (21%) not significant
Four patients in the uni-valvular and six patients in the multi-valvular endocarditis group had more than one complication.
a Chi square method.
valves are more likely to die or require early operation for
management of complications [7], the mortality rate in our
series was 21% (three patients), which is comparable with our
single-valve IE cases (18%). (Table 4). Fifty percent of the pat-
ients (seven patients) were discharged after successful medical
management alone and 29% (four patients), underwent valve
replacement.
The most common complications in our series were con-
gestive heart failure (64%) and acute renal failure (50%). Occur-
rence of embolic events (i.e. pulmonary embolism, cerebral
vascular accident, disseminated intravascular coagulation, etc.)
and splenic abscess/infarct were each 21%. Among the com-
plications, only congestive heart failure was statistically more
common in the multi-valvular versus the uni-valvular group.
In conclusion, the incidence of multi-valvular endocarditis
occurred in 18% of our series of IE, with involvement of mitral
and aortic valves being most common. Only congestive heart
failure was found to be statistically more common in multi-
valvular than uni-valvular endocarditis.
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